Reinventing sustainable access to transformative therapies.
Aradigm is the first comprehensive cell & gene therapy carve-out.
Treatments are now available that can prevent or cure diseases that have historically caused enormous suffering and mortality, by targeting the genetic or cellular causes of the disease. However, as treatments become increasingly transformative — and costly — traditional systems for payment and delivery haven’t kept pace.
Formed as a public benefit corporation, our transparent pass-through business model aligns providers, manufacturers, and purchasers around the same goal: sustainable and affordable access to transformative treatments.
Together, we are the foundation that can shift the paradigm in healthcare.
Pillars Of Impact
Patient Focus
Quality outcomes and patient experience are at the core of our model
Affordable Access
Delivering transparent, administrable CGT pricing
Sustainable Coverage
Ensuring eligible patients receive the therapies they need through reliable, equitable delivery models
Why Now?
CGT costs range from $1 - $4M+
$1–4M
Increasing approvals require improved infrastructure to ensure sustainable access for patients
A 10x increase within 3–5 years
Car-T episode costs vary by over 242% between providers, with similar outcomes
242% between providers
Stakeholder Benefits Overview
Employers & Insurers
Bend the cost curve of high-cost therapeutics while elevating clinical quality and member support
Providers
Garner predictable volume, mitigate cashflow risk, and reduce complexity
Manufacturers
Unlock new avenues for access to your cutting-edge therapies in collaboration with providers, employers, and payers
